Search results
8 sty 2024 · APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints. Article 25 September 2023. Introduction. Alzheimer disease (AD) is a neurodegenerative...
12 wrz 2024 · Studies also showed ApoE helps clear away amyloid—a job that ApoE4, which differs from ApoE2 and ApoE3 at just two amino acids, does less efficiently. The brains of APOE4 carriers not only develop more amyloid than noncarriers, but are less able to break up plaques if they do form.
19 cze 2024 · This Review provides a framework for incorporating APOE into Alzheimer’s disease (AD) clinical care by bridging recent advances in APOE and AD research with emerging clinical applications for...
18 wrz 2024 · Apolipoprotein E4 (ApoE4), the strongest genetic risk factor for sporadic Alzheimer’s disease, is also a risk factor for microvascular pathologies leading to cognitive impairment,...
Here, we review these scientific advances and propose a cell type-specific APOE4 cascade model of AD. In this model, neuronal APOE4 emerges as a crucial pathological initiator and driver of AD pathogenesis, instigating glial responses and, ultimately, neurodegeneration.
Abstract. The Apolipoprotein E ε4 (ApoE ε4) allele, encoding ApoE4, is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD). Emerging epidemiological evidence indicated that ApoE4 contributes to AD through influencing β-amyloid (Aβ) deposition and clearance.
Recent studies are now paving the way for effective apoE4-directed AD treatment approaches. Possible therapeutic approaches targeting apoE4 Schematic presentation of the apoE4-driven...
